LivaNova

LivaNova is a global medical technology company specializing in the development and provision of innovative products and therapies for the heart and head. The company was founded in 2015 through the merger of Cyberonics and Sorin and is based in London.

LivaNova offers a wide range of products and therapies, including:

• Neuromodulation: Vagus Nerve Stimulation (VNS) for the treatment of treatment-resistant depression and drug-resistant epilepsy.
• Cardiopulmonary Products: Solutions for cardiopulmonary applications.
• Sleep Apnea Therapies: Treatment options for obstructive sleep apnea.

LivaNova is committed to improving the lives of patients and their families through innovative medical technologies. The company places great emphasis on quality, integrity and ethical conduct. It strives to offer hope and promote the well-being of patients through its products and services.

Although specific sustainability goals are not explicitly mentioned in the information provided, LivaNova places great emphasis on ethical conduct and improving the quality of life for patients worldwide. Through its innovative solutions, the company contributes to the sustainable improvement of healthcare.

LivaNova employs approximately 2,900 people in over 100 countries and operates large production facilities in Italy, Melbourne, São Paulo, the USA and Germany. The company is listed on the NASDAQ under the ticker symbol "LIVN".

LivaNova is a leading company in the field of medical technology, which improves the lives of millions of people worldwide through its innovative products and therapies.

• 1 - https://en.wikipedia.org/wiki/LivaNova
• 2 - https://www.livanova.com/depression/de-de/h%C3%A4ufig-gestellte-fragen/sicherheit-von-vns-therapy-h%C3%A4ufig-gestellte-fragen
• 3 - https://www.livanova.com/en-us/about-us
• 4 - https://careers.livanova.com/us/en/
• 5 - https://investor.livanova.com/static-files/651c6e8f-fa92-42c4-bab3-ac2cf70ceac6